Twenty-four subjects with type 1 diabetes naïve to glargine and detemir were studied twice in a randomized, double-blind crossover study. Plasma glucose was clamped at 100 mg/dL for 24 hours after subcutaneous injection of 0.35 Units/kg of either Lantus® or detemir.
Study DesignIn a single-center, double-blind, 6-period, randomized, dose-response trial, 12 isoglycemic (130 mg/dL), C-peptide-negative (<0.03 nmol/L) subjects with type 1 diabetes were randomized to a specific treatment sequence encompassing 5 dose levels of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 Units/kg) and 1 dose level of NPH insulin (0.3 Units/kg).
From Plank3 and Levemir Prescribing Information.4
aGlucose infusion rate (mg/kg/min).
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††